YAP Accelerates Notch-Driven Cholangiocarcinogenesis via mTORC1 in Mice.


Journal

The American journal of pathology
ISSN: 1525-2191
Titre abrégé: Am J Pathol
Pays: United States
ID NLM: 0370502

Informations de publication

Date de publication:
09 2021
Historique:
received: 11 01 2021
revised: 24 05 2021
accepted: 27 05 2021
pubmed: 16 6 2021
medline: 14 9 2021
entrez: 15 6 2021
Statut: ppublish

Résumé

Intrahepatic cholangiocarcinoma (iCCA) is a lethal malignant neoplasm with limited therapeutic options. Previous studies have found that Notch1 overexpression alone suffices to induce iCCA in the mouse, albeit after long latency. The current study found that activation of the Yes-associated protein (Yap) proto-oncogene occurs during Notch1-driven iCCA progression. After co-expressing activated Notch1 intracellular domain (Nicd) and Yap (YapS127A) in the mouse liver, rapid iCCA formation and progression occurred in Nicd/Yap mice. Mechanistically, an increased expression of amino acid transporters and activation of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway was detected in Nicd/Yap mouse liver tumors. Significantly, the genetic deletion of Raptor, the major mTORC1 component, completely suppressed iCCA development in Nicd/Yap mice. Elevated expression of Notch1, YAP, amino acid transporters, and members of the mTORC1 pathway was also detected ubiquitously in a collection of human iCCA specimens. Their levels were associated with a poor patient outcome. This study demonstrates that Notch and YAP concomitant activation is frequent in human cholangiocarcinogenesis. Notch and YAP synergize to promote iCCA formation by activating the mTORC1 pathway.

Identifiants

pubmed: 34129844
pii: S0002-9440(21)00252-2
doi: 10.1016/j.ajpath.2021.05.017
pmc: PMC8420864
pii:
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
MAS1 protein, human 0
Proto-Oncogene Mas 0
Receptor, Notch1 0
Transcription Factors 0
YAP-Signaling Proteins 0
YAP1 protein, human 0
Yap1 protein, mouse 0
Mechanistic Target of Rapamycin Complex 1 EC 2.7.11.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1651-1667

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK026743
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA190606
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA239251
Pays : United States

Informations de copyright

Copyright © 2021 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Références

J Clin Invest. 2012 Aug;122(8):2911-5
pubmed: 22797301
J Hepatol. 2017 Dec;67(6):1194-1203
pubmed: 28733220
Biochem Biophys Res Commun. 2019 Dec 17;520(4):691-693
pubmed: 31761081
Nat Rev Clin Oncol. 2018 Feb;15(2):95-111
pubmed: 28994423
Hepatology. 2019 Dec;70(6):2003-2017
pubmed: 30737831
Cancer Res. 2020 Feb 15;80(4):757-770
pubmed: 31843982
Asian J Pharm Sci. 2020 Mar;15(2):192-206
pubmed: 32373199
Nat Rev Mol Cell Biol. 2019 Apr;20(4):211-226
pubmed: 30546055
Cancer Res. 2020 Dec 1;80(23):5305-5316
pubmed: 33067264
Liver Int. 2012 Jan;32(1):38-47
pubmed: 22098159
Cell Res. 2016 Jan;26(1):7-20
pubmed: 26658722
Hepatology. 2016 Jan;63(1):159-72
pubmed: 26389641
Lancet. 2014 Jun 21;383(9935):2168-79
pubmed: 24581682
Cancer Commun (Lond). 2020 Dec;40(12):655-680
pubmed: 33142045
Gastroenterology. 2014 Sep;147(3):690-701
pubmed: 24837480
Cancers (Basel). 2020 Sep 14;12(9):
pubmed: 32937954
Cancer Cell Int. 2019 Dec 26;19:352
pubmed: 31889904
J Hepatol. 2013 Jun;58(6):1244-5
pubmed: 23352938
Am J Pathol. 2019 Sep;189(9):1863-1877
pubmed: 31220448
Cancer Lett. 2019 Dec 28;467:29-39
pubmed: 31574293
Clin Cancer Res. 2009 Jan 15;15(2):660-7
pubmed: 19147772
Gene Expr. 2020 Jun 12;20(1):67-74
pubmed: 31253203
Oncotarget. 2017 Sep 1;8(43):73433-73447
pubmed: 29088718
Oncogene. 2018 Jun;37(24):3229-3242
pubmed: 29545603
J Hepatol. 2020 Aug;73(2):315-327
pubmed: 32173382
J Environ Pathol Toxicol. 1979 Dec;3(1-2):329-51
pubmed: 575723
Dev Cell. 2017 May 8;41(3):228-241
pubmed: 28486129
Gut. 2014 Oct;63(10):1658-67
pubmed: 24436140
Hepatology. 2013 Nov;58(5):1801-13
pubmed: 23703657
Cells. 2020 Sep 03;9(9):
pubmed: 32899180
Cancer Treat Rev. 2019 Jan;72:45-55
pubmed: 30476750
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Am J Pathol. 2020 Jul;190(7):1414-1426
pubmed: 32275903
J Clin Invest. 2016 Sep 1;126(9):3313-35
pubmed: 27548520
Lancet Oncol. 2020 May;21(5):671-684
pubmed: 32203698
Cell. 2017 Mar 9;168(6):960-976
pubmed: 28283069
Trends Cell Biol. 2015 Sep;25(9):499-513
pubmed: 26045258
Cell Mol Gastroenterol Hepatol. 2021;11(4):1095-1117
pubmed: 33232824
Cell. 2009 Feb 6;136(3):521-34
pubmed: 19203585
Hepatology. 2014 Feb;59(2):544-54
pubmed: 24002901
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Curr Opin Cell Biol. 2019 Dec;61:64-71
pubmed: 31387016
Cancer Cell. 2016 Aug 8;30(2):353-356
pubmed: 27505676
Liver Int. 2016 Aug;36(8):1176-86
pubmed: 26716908
Hepatology. 2015 Jan;61(1):200-13
pubmed: 25145583
JAMA Surg. 2014 Jun;149(6):565-74
pubmed: 24718873
World J Gastrointest Oncol. 2020 Sep 15;12(9):957-974
pubmed: 33005291
Drugs. 2020 Jun;80(9):923-929
pubmed: 32472305
Annu Rev Genet. 2018 Nov 23;52:65-87
pubmed: 30183404
Expert Opin Ther Targets. 2017 May;21(5):471-483
pubmed: 28326864
Hepatology. 2015 Nov;62(5):1497-510
pubmed: 26173433
Cell Rep. 2017 Mar 14;18(11):2780-2794
pubmed: 28297679
Clin Cancer Res. 2019 Jan 1;25(1):403-413
pubmed: 30084835
Nat Rev Mol Cell Biol. 2016 Nov;17(11):722-735
pubmed: 27507209
Hepatology. 2020 Jan;71(1):196-213
pubmed: 31211856
Oncology. 2017;93(1):67-74
pubmed: 28448997
Clin Cancer Res. 2018 Sep 1;24(17):4154-4161
pubmed: 29848569
Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12250-12255
pubmed: 27791012
Hepatology. 2016 Jun;63(6):1900-13
pubmed: 26910791
Hepatology. 2021 Jan;73 Suppl 1:49-61
pubmed: 32394479
Am J Pathol. 2014 Apr;184(4):912-923
pubmed: 24480331
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
J Clin Invest. 2015 Jun;125(6):2445-57
pubmed: 25915586

Auteurs

Xinjun Lu (X)

Department of Hepatic Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California.

Baogang Peng (B)

Department of Hepatic Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Ge Chen (G)

University of Bristol, Bristol, United Kingdom.

Mario G Pes (MG)

Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari, Italy.

Silvia Ribback (S)

Institute of Pathology, University of Greifswald, Greifswald, Germany.

Cindy Ament (C)

Institute of Pathology, University of Regensburg, Regensburg, Germany.

Hongwei Xu (H)

Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California; Department of Liver Surgery, Center of Liver Transplantation, West China Hospital of Sichuan University, Sichuan, China.

Rajesh Pal (R)

Institute of Pathology, University of Regensburg, Regensburg, Germany.

Pedro M Rodrigues (PM)

Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain; National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd), ISCIII, Madrid, Spain.

Jesus M Banales (JM)

Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain; National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd), ISCIII, Madrid, Spain; Ikerbasque, Basque Foundation for Science, Bilbao, Spain.

Matthias Evert (M)

Institute of Pathology, University of Regensburg, Regensburg, Germany.

Diego F Calvisi (DF)

Institute of Pathology, University of Regensburg, Regensburg, Germany.

Xin Chen (X)

Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California.

Biao Fan (B)

Department of Gastrointestinal Surgery, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China. Electronic address: fanbiao1986@163.com.

Jingxiao Wang (J)

Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California; School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China. Electronic address: 201801022@bucm.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH